Sparrow Pharmaceuticals has continued to expand its PROST! Phase 2 clinical trial (NCT05436652) of SPI-62 in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) with a fourth cohort.

Sparrow Pharmaceuticals today announced that the first patient has been dosed in the Phase 2 ACSpire study of SPI-62, a potent and selective HSD-1 inhibitor, for the treatment of autonomous cortisol secretion (ACS).

Sparrow Pharmaceuticals today announced the expansion of its PROST! Phase 2 clinical trial of SPI-62 in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) to include a third cohort.

Sparrow Pharmaceuticals today announced the first patient has elected to enroll in the open-label extension (OLE) phase of the RESCUE trial, a phase 2 clinical trial of SPI-62 for the treatment of ACTH-dependent Cushing’s syndrome. The long-term OLE will be open to patients who complete the initial RESCUE cross-over treatment protocol and then elect to continue to participate in the research.

Sparrow Pharmaceuticals will present the rationale that its lead candidate and HSD-1 inhibitor, SPI-62, is predicted to be associated with limited adrenal insufficiency risk in Cushing’s syndrome during a poster session at the Endocrine Society (ENDO) 2023 Annual Conference.

Sparrow Pharmaceuticals presented an ePoster on SPI-62 during a session, titled “Controlling intracellular cortisol: Can HSD-1 inhibition reduce Cushing’s syndrome morbidity and minimize adrenal insufficiency risk?” at the 25th European Congress of Endocrinology (ECE 2023).

Sparrow Pharmaceuticals has expanded its Phase 2 clinical trial of prednisolone in combination with SPI-62 for the treatment of polymyalgia rheumatica (PMR) with the introduction of a second cohort to the study.

Sparrow Pharmaceuticals today presented pharmacology data during an online poster session on SPI-62, a HSD-1 inhibitor, at the American College of Rheumatology (ACR) Convergence 2022 meeting. The presentation titled, “Toward Safer Glucocorticoid Therapy” examined the ability of SPI-62 to mitigate the adverse effects of exogenously administered corticosterone (CORT) in mouse, with results suggesting SPI-62 has the potential to prevent the adverse effects of glucocorticoids.

Sparrow Pharmaceuticals today announced that the first patient has been dosed in the RESCUE trial, a phase 2 clinical trial of SPI-62, a potent and selective HSD-1 inhibitor, for the treatment of ACTH-dependent Cushing’s syndrome.

Sparrow Pharmaceuticals today announced that the first patient has been dosed in a phase 2 clinical trial of prednisolone in combination with SPI-62, Sparrow’s potent and selective investigational HSD-1 inhibitor, for the treatment of polymyalgia rheumatica (PMR), a common autoimmune disease that causes widespread muscle pain and stiffness primarily in adults over 50. A fixed-dose combination of prednisolone and SPI-62 will be referred to as SPI-47.

Sparrow Pharmaceuticals today presented new pharmacological data during a poster session and a Rapid Communications session titled, “HPA axis modulation by a potent inhibitor indicates 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) is a main source of cortisol that can bind intracellular receptors” at the 24th European Congress of Endocrinology (ECE 2022).

Sparrow Pharmaceuticals today presented new animal model data during an in-person poster session titled, “Toward Safer Glucocorticoid Therapy of Polymyalgia Rheumatica” at the 2022 Annual European Congress of Rheumatology (EULAR 2022). The results of the study suggest that SPI-62 has the potential to mitigate adverse effects of glucocorticoids.

Sparrow Pharmaceuticals today presented new pharmacological data during a poster session and a Rapid Communications session titled, “HPA axis modulation by a potent inhibitor indicates 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) is a main source of cortisol that can bind intracellular receptors” at the 24th European Congress of Endocrinology (ECE 2022).

Sparrow Pharmaceuticals today announced that the FDA has cleared an IND that enables the company to proceed with initiating a phase 2 clinical trial to study SPI-62 for the treatment of ACTH-dependent Cushing’s syndrome. The company also announced that it has expanded its clinical capabilities by hiring Kim Hunsicker as Head of Clinical Operations and Sarah Hooper as Clinical Project Manager.

Sparrow Pharmaceuticals announced the appointment of Frank Czerwiec, MD, PhD as Chief Medical Officer and Jamie MacPherson, PharmD as Vice President of Regulatory Affairs and Quality. Dr. Czerwiec has more than 35 years of experience in industry, academia, and public service, while Dr. MacPherson brings her more than 20 years of experience as a regulatory affairs and quality assurance professional in the pharmaceutical and biotechnology industries across a wide variety of therapeutic areas.

Sparrow Pharmaceuticals presented new data at the European Congress of Endocrinology 2021 on 22-26 May 2021 as a poster presentation, “SPI-62: An investigational HSD-1 inhibitor for the treatment of Cushing syndrome”.

Sparrow Pharmaceuticals announced the closing of a $50 million Series A financing. OrbiMed led the investment round with participation by RiverVest Venture Partners and U.S. Venture Partners (USVP).